News

Under the terms of the agreement, GlaxoSmithKline (GSK) is expected to pay Ligand $5m as an upfront license fee, up to $158m in development and commercial milestones and a 16%

With this transaction, Radi Medical Systems will become part of the St Jude Medical cardiovascular division. The transaction is expected to be neutral to St Jude Medical’s consolidated

Progen will propose to shareholders a A$20 million share buyback option, to be completed prior to the merger. The combined entity will have over A$60 million cash at

The protocols for the two studies 102 and 030 were reviewed and prospectively approved by the FDA under its special protocol assessment (SPA) procedure. Both studies achieved their

In this study, the efficacy of multiple doses of 600mg of MEM 1414 on the allergen-induced asthmatic response in steroid free subjects with mild allergic asthma will be

In conjunction with this transaction, EMD Serono Canada, an affiliate of Merck KGaA, has assumed control of Oncothyreon’s facility in Edmonton, Canada, which is primarily utilized for the

The company is planning to treat amyotrophic lateral sclerosis (ALS) patients through spinal injections of its stem cells via its patented human neural stem cell technology. Neuralstem expects

ACT III is a randomized open-label, two-arm, Phase IIb/III trial comparing CDX-110 combined with temozolomide to temozolomide alone in patients with newly diagnosed glioblastoma multiforme (GBM). Only the

An open-label Phase Ib clinical trial is expected to enroll up to 42 patients with locally advanced or metastatic solid tumors in order to evaluate the safety and efficacy of